| Literature DB >> 19969466 |
Sharmila Sivendran1, Victoria Jones, Dianqing Sun, Yi Wang, Anna E Grzegorzewicz, Michael S Scherman, Andrew D Napper, J Andrew McCammon, Richard E Lee, Scott L Diamond, Michael McNeil.
Abstract
High-throughput screening of 201,368 compounds revealed that 1-(3-(5-ethyl-5H-[1,2,4]triazino[5,6-b]indol-3-ylthio)propyl)-1H-benzo[d]imidazol-2(3H)-one (SID 7975595) inhibited RmlC a TB cell wall biosynthetic enzyme. SID 7975595 acts as a competitive inhibitor of the enzyme's substrate and inhibits RmlC as a fast-on rate, fully reversible inhibitor. An analog of SID 7975595 had a K(i) of 62nM. Computer modeling showed that the binding of the tethered two-ringed system into the active site occurred at the thymidine binding region for one ring system and the sugar region for the other ring system. Copyright 2009 Elsevier Ltd. All rights reserved.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19969466 PMCID: PMC2818544 DOI: 10.1016/j.bmc.2009.11.033
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641